Method for treating diseases caused by pathogenic Anti-ganglioside antibodies
By using intermittent dosing and combining it with immunosuppressants or prophylactic antibiotics, the risks associated with IdeS in high-titer antibody populations have been mitigated, achieving safe and effective control of pathogenic antiganglioside antibody diseases and improving patient symptoms.
Patent Information
- Application Number
- PCT/CN2026/096519
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-02-11
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
The existing immunoglobulin G degrading enzyme IdeS poses a risk of hypersensitivity reactions when used in individuals with high antibody titers, and repeated administration may lead to anti-drug antibody reactions, limiting its efficacy and safety in the treatment of pathogenic antiganglioside antibody diseases.
An interval dosing regimen was adopted, including administering a first dose of immunoglobulin G degrading enzyme (0.1 mg/kg to 1 mg/kg) to subjects on day 1, followed by supplemental dosing at intervals of 1–14 days, combined with immunosuppressant or prophylactic antibiotic therapy, to optimize the dosing regimen to control pathogenic antibody levels.
It effectively controls the level of pathogenic antibodies in patients, reduces the production of unwanted anti-drug antibodies, improves the safety and effectiveness of treatment, and significantly improves disease symptoms such as GBS-DS and muscle strength recovery.
Smart Images

Figure CN2026096519_19112026_PF_FP_ABST
Abstract
Description
Methods for treating diseases caused by pathogenic antiganglioside antibodies
[0001] Priority Declaration
[0002] This invention claims priority to the following three patent applications: Chinese patent application No. 2025106137542, filed on May 12, 2025; Chinese patent application No. 2026102064142, filed on February 11, 2026; and Chinese patent application No. 2026102064797, filed on February 11, 2026. The entire contents of these three patent applications are incorporated herein by reference. Technical Field
[0003] This disclosure relates to the field of biotechnology, and more specifically to a method for treating diseases caused by pathogenic antiganglioside antibodies using immunoglobulin-degrading enzymes. Background Technology
[0004] Gangliosides are important molecules on the surface of nerve cells, participating in nerve signal transduction and cell adhesion. In certain disease states, the immune system mistakenly recognizes gangliosides as foreign antigens, producing antibodies that attack nerve tissue. Common diseases include Guillain-Barré syndrome (GBS): an acute immune-mediated polyradiculoneuropathy in which antibodies against GM1, GD1a, and GQ1b can be detected in some patients.
[0005] Guillain-Barré syndrome (GBS) is an immune-mediated acute inflammatory peripheral neuropathy with an acute onset, typically peaking within about two weeks. GBS can occur at any age and in any season, with an incidence rate of approximately (0.30–6.08) / 100,000. It includes two main types: classic GBS and variant GBS. GBS presents with an acute onset and a monophasic course; 50%–80% of patients reach their peak condition within two weeks, and almost all patients reach their peak within four weeks, after which the condition tends to stabilize or improve. GBS has a mortality rate of 5%–15%, a disability rate of nearly 20%, and requires mechanical ventilation in 25% of patients.
[0006] The 2024 Chinese Guidelines for the Diagnosis and Treatment of Guillain-Barré Syndrome recommend treatment options including intravenous immunoglobulin (IVIG) and plasma exchange, both of which are effective with no significant difference in efficacy. However, IVIG is simpler to administer and is the preferred option in clinical practice. The IVIG treatment regimen is 400 mg / kg / day, once daily, administered via intravenous infusion for 5 consecutive days.
[0007] Developed by Hansa Biopharma AB, Imlifidase is an immunoglobulin G degrading enzyme (IdeS) of Streptococcus pyogenes, capable of specifically cleaving immunoglobulin G (IgG). This characteristic makes IdeS a potential application in the treatment of autoimmune diseases and antibody-mediated transplant rejection. This drug has been approved for marketing in the EU for the treatment of hypersensitivity renal transplant desensitization. For GBS, a Phase II clinical trial has been completed. The administration method is: Day 1, a single intravenous injection of Imlifidase (0.25 mg / kg); Days 3-7, IVIG (400 mg / kg / day), once daily, intravenous infusion for 5 consecutive days. In other words, only one injection of Imlifidase is administered, and it must be combined with IVIG treatment.
[0008] However, IdeS is a virulence factor of human pathogens, and due to early infection with Streptococcus pyogenes, a significant portion of the population has pre-existing IgG antibodies against IdeS (Anti-Drug Antibodies, ADAs). A clinical study of Imlifidase found that 10 out of 130 subjects had IdeS-specific IgG levels below the cutoff (2.0 mg / L); the median anti-IdeS IgG level was 6.1 mg / L, and the 80th percentile was 15 mg / L. These anti-IdeS antibodies may increase the risk of hypersensitivity / infusion-like reactions to imlifidase (Winstedt L et al. (2015). PLoS ONE 10(7)), limiting the use of IdeS in high-titer ADA populations. Furthermore, because anti-IdeS antibodies are widely present in patients, anti-drug antibodies are rapidly generated after the first administration of IdeS. For example, in another phase II clinical study of Imlifidase (J Am Soc Nephrol. 2022 Apr; 33(4):829–838. doi:10.1681 / ASN.2021111460), the pre-treatment ADA levels of the subjects varied, ranging from 3.5 to 16.7 mg / L. Despite the use of steroids and cyclophosphamide (CYC), ADA levels in the samples rose sharply on day 14. Therefore, although IdeS can be given a second time within 24 hours, the dosing interval should not exceed 24 hours. However, even continuous dosing within 24 hours cannot effectively clear and prevent the formation of new immunoglobulins in the body, and thus cannot effectively address the recurrence of pathogenic antibodies in the patient's body, or eliminate the negative effects caused by autoimmune reactions.
[0009] WO2024008943A1 relates to a pretreatment protocol for cell transplantation in sensitized subjects, comprising at least two administrations of an enzyme that inactivates serum IgG molecules in the subject. Given that many enzymes with this function are bacterial (often pathogenic) in origin, the second dose may present problems due to the patient's immune response to it. For example, IdeS is a bacterial enzyme derived from Streptococcus pyogenes, which most people have been exposed to and developed immune memory for. This can lead to rapid and sometimes very strong anti-drug antibody responses, making repeated dosing impractical. Summary of the Invention
[0010] The first aspect of this disclosure provides a method for treating a disease caused by pathogenic antiganglioside antibodies, the method comprising:
[0011] a. Administer a first dose of immunoglobulin G degrading enzyme, approximately 0.1 mg / kg to approximately 1 mg / kg, intravenously to the subject on day 1; and
[0012] b. Administer immunoglobulin G degrading enzymes to the subject at intervals of 1 to 14 days, at a dose of approximately 0.1 mg / kg to approximately 1 mg / kg.
[0013] In an optional embodiment, the method may include administering the subject approximately 0.1 mg / kg to approximately 1 mg / kg of immunoglobulin G degrading enzyme within 24 hours after the first administration of the enzyme.
[0014] In an optional embodiment, the method may include repeating step b at least once; preferably twice or three times.
[0015] In an alternative embodiment, the subject may also receive treatment with at least one immunosuppressant or prophylactic antibiotic.
[0016] In an optional embodiment, if the condition progressively worsens 12 hours after the last administration of immunoglobulin G degrading enzyme, IVIG and PE salvage therapy can be initiated; in an optional embodiment, the progressive worsening of the condition includes severe respiratory distress.
[0017] In an optional embodiment, the antiganglioside antibody includes at least one of antiGM1 antibody, antiGM2 antibody, antiGM3 antibody, antiGM4 antibody, antiGD1a antibody, antiGD1b antibody, antiGD2 antibody, antiGQ1b antibody, antiGT1a antibody, antiGT1b antibody, or antisulfatide antibody.
[0018] In alternative embodiments, the disease includes Guillain-Barré syndrome (GBS), Miller-Fischer syndrome (MFS), multifocal motor neuropathy (MMN), or chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
[0019] In an optional embodiment, the subject is an acute-phase GBS patient; in an optional embodiment, the onset time of the subject is ≤10 days.
[0020] In an alternative implementation, the subject is not a subject with selective immunoglobulin A (IgA) deficiency.
[0021] In an optional embodiment, the subject does not have a history of polyneuropathy due to other causes; in an optional embodiment, the history of polyneuropathy due to other causes is selected from the group consisting of diabetes, alcohol poisoning, peripheral polyneuropathy related to severe vitamin B1 deficiency, and porphyria, excluding mild sensory neuropathy.
[0022] In an optional embodiment, the subject did not receive immunosuppressive therapy within one month prior to treatment with immunoglobulin G degrading enzymes. Preferably, the subject did not receive azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, or prednisolone within one month prior to treatment.
[0023] In an optional implementation, the subject is not a subject suffering from severe comorbidities. Preferably, the subject is not a subject suffering from malignant tumors, severe cardiovascular disease, severe chronic obstructive pulmonary disease (COPD), or severe infection.
[0024] In an optional embodiment, the dosage of immunoglobulin G degrading enzyme in each dose may be the same or different; in an optional embodiment, the dosage of immunoglobulin G degrading enzyme in the first dose is different from that in the supplementary dose, while the dosage of immunoglobulin G degrading enzyme in the supplementary dose is the same.
[0025] In an optional embodiment, the dosage of the first dose of immunoglobulin G degrading enzyme is about 0.1 mg / kg to about 1 mg / kg, and can be about 0.1 mg / kg to about 0.4 mg / kg, including but not limited to about 0.1 mg / kg, about 0.15 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.3 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 0.95 mg / kg, or about 1 mg / kg. The dosage of the supplemental immunoglobulin G degrading enzyme is approximately 0.1 mg / kg to approximately 0.3 mg / kg, optionally ranging from approximately 0.1 mg / kg to approximately 0.3 mg / kg, including but not limited to approximately 0.1 mg / kg, approximately 0.15 mg / kg, approximately 0.2 mg / kg, approximately 0.25 mg / kg, approximately 0.3 mg / kg, approximately 0.35 mg / kg, approximately 0.4 mg / kg, approximately 0.45 mg / kg, approximately 0.5 mg / kg, approximately 0.55 mg / kg, approximately 0.6 mg / kg, approximately 0.65 mg / kg, approximately 0.7 mg / kg, approximately 0.75 mg / kg, approximately 0.8 mg / kg, approximately 0.85 mg / kg, approximately 0.9 mg / kg, approximately 0.95 mg / kg, or approximately 1 mg / kg.
[0026] In an optional embodiment, the dosage of at least one dose of immunoglobulin G degrading enzyme is about 100% to about 20% of the dosage of the previous dose of immunoglobulin G degrading enzyme, optionally about 80% to about 40%, optionally about 50% to about 70%, optionally about 60%.
[0027] In an optional embodiment, the dosage of the first dose of immunoglobulin G degrading enzyme is 0.25 mg / kg; the dosage of the supplementary dose of immunoglobulin G degrading enzyme is 0.25 mg / kg or 0.15 mg / kg.
[0028] In an optional embodiment, the method can reduce the immunoglobulin G degradation enzyme level in the subject to about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% of the level before administration, 45 min to 6 h after administration.
[0029] In an optional embodiment, the method can reduce the immunoglobulin G degradation enzyme level in the subject to about 5 g / L, about 4 g / L, about 3 g / L, about 2 g / L, about 1 g / L or about 0.5 g / L or below 45 min to 6 h after administration.
[0030] In an optional embodiment, the administration interval of the immunoglobulin G degrading enzyme is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 9 days, 10 days, 13 days, or 14 days.
[0031] In an optional embodiment, the immunoglobulin G degrading enzyme is selected from IdeS, IdeE, IdeZ, IdeP, IdeSORK or their mutants.
[0032] In an optional embodiment, the immunoglobulin G degrading enzyme is a low-immunogenic immunoglobulin G degrading enzyme. Optionally, the immunogenic immunoglobulin G degrading enzyme has even lower immunogenicity than IdeS.
[0033] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme has at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with the amino acid sequence shown in any one of SEQ ID NO:1 to 13.
[0034] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme includes the amino acid sequence shown in any one of SEQ ID NO:1 to 13.
[0035] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme includes any one of the amino acid sequences shown in SEQ ID NO:1 to 11,16.
[0036] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme is shown in SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:13, or SEQ ID NO:16. Optionally, the immunoglobulin G degrading enzyme is the immunoglobulin G degrading enzyme with the amino acid sequence shown in SEQ ID NO:2.
[0037] In an optional implementation, the immunoglobulin G degrading enzymes in each dose may be the same or different.
[0038] In an optional implementation, the method includes:
[0039] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1; and
[0040] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2;
[0041] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0042] In an optional implementation, the method includes:
[0043] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1;
[0044] b. Administer supplemental dose of 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 on day 4; and
[0045] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2.
[0046] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0047] In an optional implementation, the method includes:
[0048] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1;
[0049] b. Administer supplemental dose of 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 on day 4; and
[0050] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2;
[0051] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0052] In an optional implementation, the method includes:
[0053] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1;
[0054] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2;
[0055] c. On day 7, administer supplemental 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2; and
[0056] d. On day 10, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2.
[0057] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0058] In an optional implementation, the method includes:
[0059] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1; and
[0060] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16;
[0061] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0062] In an optional implementation, the method includes:
[0063] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1;
[0064] b. Administer supplemental dose of 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 on day 4; and
[0065] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16.
[0066] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0067] In an optional implementation, the method includes:
[0068] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1;
[0069] b. On day 4, administer supplemental dose of 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16; and
[0070] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16;
[0071] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0072] In an optional implementation, the method includes:
[0073] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1;
[0074] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16;
[0075] c. On day 7, administer supplemental dose of 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16; and
[0076] d. On day 10, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16.
[0077] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0078] A second aspect of this disclosure provides a pharmaceutical composition comprising an immunoglobulin G degrading enzyme sufficient for administration of the above-described method for treating diseases caused by pathogenic antiganglioside antibodies, and pharmaceutically acceptable excipients.
[0079] A third aspect of this disclosure provides a pharmaceutical combination comprising at least one immunoglobulin G degrading enzyme sufficient for administering the above-described method of treating a disease caused by pathogenic antigangliosyl antibodies, and at least one of the above-described immunosuppressants and / or at least one of the above-described prophylactic antibiotics.
[0080] The advantages of this disclosure are: by administering supplemental doses of IgG degrading enzyme to subjects, the pathogenic antibodies in the patient's body are rapidly controlled at a low level and maintained for a relatively long period of time, without the subject developing unwanted ADA, thereby improving the safety and efficacy of treatment. After administering supplemental doses of IgG degrading enzyme to subjects, the patients' GBS-DS and MRC scores improved, and muscle strength was significantly restored. Attached Figure Description
[0081] Figure 1 shows the results of IgG concentration detection in subjects during the two-dose regimen.
[0082] Figure 2 shows the results of the detection of the average IgG concentration in the subjects during the two-dose regimen.
[0083] Figure 3 shows the results of ADA titer detection in subjects during the two-dose regimen.
[0084] Figure 4 shows the results of detecting the concentration of anti-GBM antibodies in the subjects during the two-dose regimen.
[0085] Figure 5 shows the results of IgG concentration detection in subjects during the three-dose regimen.
[0086] Figure 6 shows the results of the detection of the average IgG concentration in the subjects during the three-dose regimen.
[0087] Figure 7 shows the results of ADA titer detection in subjects during the three-dose regimen.
[0088] Figure 8 shows the results of detecting the concentration of anti-GBM antibodies in the subjects during the three-dose regimen.
[0089] Figure 9 shows the progression of GBS in the subject during the three-dose regimen.
[0090] Figure 10 shows the changes in ADA (indicated by SNR values) in animals under the regimens of IDEE-2 and HIGES2 alone and in combination with immunosuppressive drugs in Example 4. Detailed Implementation
[0091] Based on the above content of this disclosure, and in accordance with common technical knowledge and practices in the field, various other modifications, substitutions, or alterations can be made without departing from the basic technical ideas of this disclosure.
[0092] I. Definition
[0093] Unless otherwise expressly stated, throughout the specification and claims, the term "comprising" or its variations such as "including" or "comprises" shall be understood to include the stated elements or components without excluding other elements or other components.
[0094] The terms “subject” and “patient” are used interchangeably and generally refer to humans.
[0095] The term "immunoglobulin G degrading enzyme" or "IgG degrading enzyme" refers to a functional polypeptide that possesses immunoglobulin G degrading enzyme activity. Common immunoglobulin G degrading enzymes are cysteine proteases derived from Streptococcus, including but not limited to IdeE (Streptococcus Equi), IdeZ (Streptococcus zooepidemicus), IdeP, and IdeS (Streptococcus pyogenes). Without limitation, the immunoglobulin G degrading enzymes disclosed herein also include engineered IdeE, IdeZ, IdeP, IdeS, or mutants thereof. Currently known IgG degrading enzymes include those from the literature (Lannergard, J. and B. Guss. 2006. FEMS Microbiol Lett 262(2):230-235; Hulting, G. et al., (2009). FEMS Microbiol Lett 298(1):44-50), as well as immunoglobulin degrading enzymes disclosed in WO2016128559A1, WO2016128558A1, WO2022223818A1, WO2021254479A1, WO2023116817A1, WO2025030053A1, and WO2024206953A2, and all enzymes and their variants that have the above-mentioned immunoglobulin cleavage activities. Variants of these known enzymes can also perform the same function. Optionally, the immunoglobulin G degrading enzyme has low immunogenicity, for example, with little or no pre-existing antibodies in the subject. Optionally low immunogenic immunoglobulin G degrading enzymes include IdeE, IdeZ, IdeP, and their mutants, such as the immunoglobulin G degrading enzymes shown in sequences 1–11, 16. The term “IdeS” or “IDES” refers to a cysteine protease derived from Streptococcus pyogenes that has the ability to specifically cleave immunoglobulin G (IgG). Without limitation, the IdeS described in this disclosure refers to wild-type IdeS or its mutants. An exemplary IdeS is imlifidase (Idefirix), whose amino acid sequence is shown in SEQ ID NO:12.
[0096] The term "IdeE" or "IDEE" comes from *Streptococcus equi* ssp. equi, a pathogenic bacterium in horses, and shares approximately 70% sequence homology with IdeS. Both IdeE and IdeS cleave IgG at exactly the same location, exhibiting highly reproducible and specific cleavage, and have very similar substrate ranges.
[0097] The term "mutant" includes amino acid insertion mutants, amino acid addition mutants, amino acid deletion mutants, and / or amino acid substitution mutants. The variant sequence may have at least 80%, at least 85%, preferably at least 90%, at least 95%, at least 98%, or at least 99% identity with the template sequence.
[0098] The term "ganglioside" refers to sialic acid containing glycosphingolipids that exhibit structural and functional polymorphisms and are widely distributed throughout the human body. They play a crucial role in protecting us from immune attacks, but they can also become targets of autoimmunity and act as receptors for microorganisms (such as influenza viruses) and toxins (such as cholera toxin). The expression patterns of gangliosides vary across different tissues, life stages, and animal species.
[0099] The term "autoantibody-mediated disease" refers to a class of illnesses caused by the immune system mistakenly attacking the body's own tissues. These diseases are collectively known as autoantibody-mediated diseases (AD). A characteristic feature of AD is the presence of antibodies against the body's own components. These antibodies can cause damage or dysfunction of organs and tissues; they are also called "pathogenic IgG antibodies." The level of pathogenic IgG antibodies can usually be detected using methods such as ELISA or SDS-PAGE. (Kühnl, Alexander et al. "Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay." Frontiers in Medicine vol.9 915754.4 Jul.2022).
[0100] The term "disease caused by pathogenic antiganglioside antibodies" refers to a group of diseases caused by the body's immune system producing antibodies against gangliosides, leading to damage to the nervous system. Gangliosides are important molecules on the surface of nerve cells, participating in nerve signal transduction and cell adhesion. In certain disease states, the immune system mistakenly recognizes gangliosides as foreign antigens, producing antibodies that attack nerve tissue. Antiganglioside antibodies (AGAs) can attack the immune function of certain cells (such as neurons) and neutralize their complement, inhibiting complement activity. Common diseases include: Guillain-Barré syndrome (GBS): an acute immune-mediated polyradiculoneuropathy; some patients may have detectable antibodies against GM1, GD1a, and GQ1b. Its pathogenesis is related to antibodies produced after infection attacking gangliosides. Multifocal motor neuropathy (MMN): characterized by asymmetrical limb weakness, often accompanied by motor nerve conduction block; anti-GM1 antibodies are mostly IgM. Chronic inflammatory demyelinating polyradiculopathy (CIDP): Although the main pathogenesis of CIDP is not fully understood, antiganglioside antibodies can be detected in some patients, and these antibodies may be involved in its pathological process.
[0101] Guillain-Barré syndrome (GBS) is divided into two main types. The first type is classic GBS, characterized by weakness in all four limbs, with or without involvement of cranial, sensory, and autonomic nerves. This includes acute inflammatory demyelinating polyneuropathies (AIDP), acute motor axonal neuropathy (AMAN), and acute motor-sensory axonal neuropathy (AMSAN), with the first two being the most common. The second type is variant GBS, such as Miller-Fisher syndrome (MFS), Bickerstaff brainstem encephalitis, pure sensory type, pharyngeal-brachial type, and paraplegic type. Except for MFS, the other types are relatively rare.
[0102] The term "treatment" includes the suppression, relief, prevention, or elimination of one or more symptoms or side effects associated with the disease, condition, or disorder being treated. The term "effective dose" or "therapeutic effective dose" refers to a dose sufficient to treat, suppress, or reduce one or more symptoms of the treated disease state or otherwise provide the desired pharmacological and / or physiological effect. Precise dosages will vary depending on a variety of factors, such as subject-dependent variables (e.g., age, immune system health, etc.), the disease or disorder, and the treatment administered. The effect of an effective dose can be relative to a control. These controls are known in the art and discussed herein, and can be, for example, the condition of the subject before or without administration of the drug or combination of drugs, or, in the case of a combination of drugs, the combined effect can be compared to the effect of administration of only one drug.
[0103] The term "immunogenicity" refers to the property of an antigen to elicit an immune response; that is, the ability of an antigen to stimulate specific immune cells, causing them to activate, proliferate, and differentiate, ultimately producing immune effector substances such as antibodies and sensitized lymphocytes. Low immunogenicity, as described above, means that the antigen elicits a weak immune response in the immune system, making it difficult to stimulate an effective immune reaction.
[0104] There are many methods for detecting ADA. These methods include, but are not limited to: a) immunoassays based on bridging ELISA; b) highly sensitive binding assays based on electrochemiluminescence (ECL) or surface plasmon resonance (SPR); c) neutralizing antibody function assays evaluated using reporter gene assays (RGA) or competitive ELISA; d) and supplementary validation methods such as liquid chromatography-mass spectrometry (LC-MS) or radioimmunoassay (RIA); e) other novel detection methods, such as ImmunoCAP, Winstedt, Lena et al. “Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity.” PLOS 1 vol. 10, 7e013 2011.15 Jul. 2015.
[0105] The term "approximately" refers to a given number within plus or minus 1% to 10%.
[0106] The term "dosing interval" refers to the time interval between two administrations. Dosing intervals can be measured in days or hours. Without limitation, when the dosing interval is measured in days, only the date difference between administrations is calculated, not the specific time difference. For example, a 1-day interval means administration on D1 and D3 respectively. In this disclosure, the dosing interval can be determined based on the level of pathogenic IgG antibodies in the patient's body; for example, if the level of pathogenic IgG antibodies in the patient's body exceeds a certain risk value, the patient may be given the next dose of IgG degrading enzyme.
[0107] The term "immunosuppressant" refers to drugs that inhibit the body's immune response. They suppress the proliferation and function of cells involved in the immune response (such as T cells and macrophages like B cells), thereby reducing antibody-mediated immune responses and inducing immune tolerance. These include glucocorticoids, alkylating agents, antimetabolites, nucleotide reductase or tyrosine kinase inhibitors, herbal medicines, calcineurin inhibitors, rapamycin target molecule inhibitors, protein drugs, or monoclonal antibodies. The glucocorticoids include prednisone, prednisolone, methylprednisolone, methylprednisolone, or dexamethasone; the alkylating agents include cyclophosphamide, busulfan, thiotepa, or chlorambucil; the antimetabolites include mycophenolate mofetil, methotrexate, mycophenolate mofetil, azathioprine, mercaptopurine, or imidazolidin; the nucleotide reductase or tyrosine kinase inhibitors include hydroxyurea, penicillamine, or leflunomide; the herbal medicines mainly include Tripterygium wilfordii glycosides or total glucosides of paeony; calcineurin inhibitors such as cyclosporine, tacrolimus, or mycophenolate mofetil; rapamycin target molecule inhibitors such as rapamycin, sirolimus, or guanitolimus; and the protein drugs include complement inhibitors, cytokine inhibitors, innate immunosuppressants, immune cell and plasma cell inhibitors, or tolerance inducers. Furthermore, the protein drugs include antibodies against CD40, CD154, CD20, CD38, CD19, CD27, TNF-α, and IL-6. More specifically, the antibodies are rituximab, ofafatumumab, ocrelizumab, obinutuzumab, ublituximab, zuberitamab, ripertamab, ibritumomab tiuxetan, MIL62, repertoire, daratumumab, isatuximab, Felzartamab, Mezagitamab, basiliximab, TAK-079, CM313, SC301SC, infliximab, adalimumab, cetolizumab, golimumab, tocilizumab, or Clazakizumab.
[0108] The term "pharmaceutical composition" means a composition comprising the therapeutic agents described in this disclosure, such as immunoglobulin G degrading enzymes, and at least one pharmaceutically acceptable ingredient selected from the following, depending on the manner of administration and the nature of the dosage form: including, but not limited to, carriers, diluents, adjuvants, excipients, preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, fragrances, antibacterial agents, antifungal agents, lubricants, dispersants, thermosensitive materials, temperature regulators, adhesives, stabilizers, suspending agents, etc. Without limitation, the pharmaceutical composition may also comprise a second therapeutic agent.
[0109] The term "drug combination" includes drug packets, drug boxes, or combination drugs. Taking a two-component drug as an example, components A and B can be mixed together to form a single dosing unit, or they can be separate dosing units. A and B can be used together as a single drug, for example, having the same marketing authorization, or they can be used separately as independent drugs, for example, having different marketing authorizations. The two components can be used together, simultaneously, continuously, or separately. Unrestricted, the drug combinations disclosed herein comprise two identical or different IgG degrading enzymes, for example, the unit dose of the first dose of IgG degrading enzyme is about 8 mg to about 40 mg, optionally about 8 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 18 mg, 20 mg, 22 mg, 24 mg, 26 mg, 28 mg, 30 mg, 32 mg, 34 mg, 36 mg, 38 mg or 40 mg; for example, the unit dose of the second dose of IgG degrading enzyme is about 5 mg to about 20 mg, optionally about 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg or 20 mg.
[0110] II. Detailed Description of the Invention
[0111] The first aspect of this disclosure provides a method for treating a disease caused by pathogenic antiganglioside antibodies, the method comprising:
[0112] a. Administer a first dose of immunoglobulin G degrading enzyme, approximately 0.1 mg / kg to approximately 1 mg / kg, intravenously to the subject on day 1; and
[0113] b. Administer immunoglobulin G degrading enzymes to the subject at intervals of 1 to 14 days, at a dose of approximately 0.1 mg / kg to approximately 1 mg / kg.
[0114] In an optional embodiment, the method includes administering the subject approximately 0.1 mg / kg to approximately 1 mg / kg of immunoglobulin G degrading enzyme within 24 hours after the first administration of the enzyme.
[0115] In an optional embodiment, the method includes repeating step b at least once; in an optional embodiment, the method includes repeating step b two or three times.
[0116] In an alternative embodiment, the subject may also receive treatment with at least one immunosuppressant or prophylactic antibiotic.
[0117] In an optional embodiment, if the condition progressively worsens 12 hours after the last administration of immunoglobulin G degrading enzyme, IVIG and PE salvage therapy can be initiated; in an optional embodiment, the progressive worsening of the condition includes severe respiratory distress.
[0118] In an optional embodiment, the antiganglioside antibody includes at least one of antiGM1 antibody, antiGM2 antibody, antiGM3 antibody, antiGM4 antibody, antiGD1a antibody, antiGD1b antibody, antiGD2 antibody, antiGQ1b antibody, antiGT1a antibody, antiGT1b antibody, or antisulfatide antibody.
[0119] In alternative embodiments, the disease includes Guillain-Barré syndrome (GBS), Miller-Fischer syndrome (MFS), multifocal motor neuropathy (MMN), or chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
[0120] In an optional embodiment, the subject is an acute-phase GBS patient; optionally, the onset time of the subject is ≤10 days.
[0121] In an alternative implementation, the subject is not a subject with selective immunoglobulin A (IgA) deficiency.
[0122] In an optional embodiment, the subject does not have a history of polyneuropathy due to other causes; optionally, the history of polyneuropathy due to other causes is selected from the group consisting of diabetes, alcoholism, peripheral polyneuropathy related to severe vitamin B1 deficiency, and porphyria, excluding mild sensory neuropathy.
[0123] In an optional embodiment, the subject did not receive immunosuppressive therapy within one month prior to treatment with immunoglobulin G degrading enzymes. Optionally, the subject did not receive azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, or prednisolone within one month prior to treatment.
[0124] In an optional embodiment, the subject is not a subject suffering from severe comorbidities. In an optional embodiment, the subject is not a subject suffering from malignant tumors, severe cardiovascular disease, severe chronic obstructive pulmonary disease (COPD), or severe infection.
[0125] In an optional embodiment, the dosage of immunoglobulin G degrading enzyme in each dose may be the same or different; in an optional embodiment, the dosage of immunoglobulin G degrading enzyme in the first dose is different from that in the supplementary dose, while the dosage of immunoglobulin G degrading enzyme in the supplementary dose is the same.
[0126] In an optional embodiment, the dosage of the first dose of immunoglobulin G degrading enzyme is about 0.1 mg / kg to about 1 mg / kg, and can be about 0.1 mg / kg to about 0.4 mg / kg, including but not limited to about 0.1 mg / kg, about 0.15 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.3 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 0.95 mg / kg, or about 1 mg / kg. The dosage of the supplemental immunoglobulin G degrading enzyme is approximately 0.1 mg / kg to approximately 0.3 mg / kg, optionally ranging from approximately 0.1 mg / kg to approximately 0.3 mg / kg, including but not limited to approximately 0.1 mg / kg, approximately 0.15 mg / kg, approximately 0.2 mg / kg, approximately 0.25 mg / kg, approximately 0.3 mg / kg, approximately 0.35 mg / kg, approximately 0.4 mg / kg, approximately 0.45 mg / kg, approximately 0.5 mg / kg, approximately 0.55 mg / kg, approximately 0.6 mg / kg, approximately 0.65 mg / kg, approximately 0.7 mg / kg, approximately 0.75 mg / kg, approximately 0.8 mg / kg, approximately 0.85 mg / kg, approximately 0.9 mg / kg, approximately 0.95 mg / kg, or approximately 1 mg / kg.
[0127] In an optional embodiment, the dosage of at least one dose of immunoglobulin G degrading enzyme is about 100% to about 20% of the dosage of the previous dose of immunoglobulin G degrading enzyme, optionally about 80% to about 40%, optionally about 50% to about 70%, optionally about 60%.
[0128] In an optional embodiment, the dosage of the first dose of immunoglobulin G degrading enzyme is 0.25 mg / kg; the dosage of the supplementary dose of immunoglobulin G degrading enzyme is 0.25 mg / kg or 0.15 mg / kg.
[0129] In an optional embodiment, the method can reduce the immunoglobulin G degradation enzyme level in the subject to about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% of the level before administration, 45 min to 6 h after administration.
[0130] In an optional embodiment, the method can reduce the immunoglobulin G degradation enzyme level in the subject to about 5 g / L, about 4 g / L, about 3 g / L, about 2 g / L, about 1 g / L or about 0.5 g / L or below 45 min to 6 h after administration.
[0131] In an optional embodiment, the administration interval of the immunoglobulin G degrading enzyme is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 9 days, 10 days, 13 days, or 14 days.
[0132] In an optional embodiment, the immunoglobulin G degrading enzyme is selected from IdeS, IdeE, IdeZ, IdeP, IdeSORK or their mutants.
[0133] In an optional embodiment, the immunoglobulin G degrading enzyme is a low-immunogenic immunoglobulin G degrading enzyme. In an optional embodiment, the immunogenic immunoglobulin G degrading enzyme has lower immunogenicity than IdeS.
[0134] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme has at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with the amino acid sequence shown in any one of SEQ ID NO:1 to 13.
[0135] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme includes the amino acid sequence shown in any one of SEQ ID NO:1 to 13.
[0136] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme includes any one of the amino acid sequences shown in SEQ ID NO:1 to 11,16.
[0137] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme is shown in SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:13, or SEQ ID NO:16. In an optional embodiment, the immunoglobulin G degrading enzyme is the immunoglobulin G degrading enzyme with the amino acid sequence shown in SEQ ID NO:2.
[0138] In an optional implementation, the immunoglobulin G degrading enzymes in each dose may be the same or different.
[0139] In an optional implementation, the method includes:
[0140] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1; and
[0141] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2;
[0142] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0143] In an optional implementation, the method includes:
[0144] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1;
[0145] b. Administer supplemental dose of 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 on day 4; and
[0146] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2.
[0147] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0148] In an optional implementation, the method includes:
[0149] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1;
[0150] b. Administer supplemental dose of 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 on day 4; and
[0151] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2;
[0152] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0153] In an optional implementation, the method includes:
[0154] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1;
[0155] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2;
[0156] c. On day 7, administer supplemental 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2; and
[0157] d. On day 10, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2.
[0158] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0159] In an optional implementation, the method includes:
[0160] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1; and
[0161] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16;
[0162] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0163] In an optional implementation, the method includes:
[0164] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1;
[0165] b. Administer supplemental dose of 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 on day 4; and
[0166] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16.
[0167] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0168] In an optional implementation, the method includes:
[0169] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1;
[0170] b. On day 4, administer supplemental dose of 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16; and
[0171] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16;
[0172] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0173] In an optional implementation, the method includes:
[0174] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1;
[0175] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16;
[0176] c. On day 7, administer supplemental dose of 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16; and
[0177] d. On day 10, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16.
[0178] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0179] A second aspect of this disclosure provides a method for treating Guillain-Barré syndrome (GBS), the method comprising:
[0180] a. Administer a first dose of immunoglobulin G degrading enzyme, approximately 0.1 mg / kg to approximately 1 mg / kg, intravenously to the subject on day 1; and
[0181] b. Administer immunoglobulin G degrading enzymes to the subject at intervals of 1 to 14 days, at a dose of approximately 0.1 mg / kg to approximately 1 mg / kg.
[0182] In an optional embodiment, the method includes administering the subject approximately 0.1 mg / kg to approximately 1 mg / kg of immunoglobulin G degrading enzyme within 24 hours after the first administration of the enzyme.
[0183] In an optional embodiment, the method includes repeating step b at least once; in an optional embodiment, the method includes repeating step b two or three times.
[0184] In an alternative embodiment, the subject may also receive treatment with at least one immunosuppressant or prophylactic antibiotic.
[0185] In an optional embodiment, if the condition progressively worsens 12 hours after the last administration of immunoglobulin G degrading enzyme, IVIG and PE salvage therapy can be initiated; in an optional embodiment, the progressive worsening of the condition includes severe respiratory distress.
[0186] In an optional embodiment, the subject is an acute-phase GBS patient; in an optional embodiment, the onset time of the subject is ≤10 days.
[0187] In an alternative implementation, the subject is not a subject with selective immunoglobulin A (IgA) deficiency.
[0188] In an optional embodiment, the subject has no history of polyneuropathy for other reasons; in an optional embodiment, the medical history is selected from the group consisting of diabetes, alcoholism, peripheral polyneuropathy related to severe vitamin B1 deficiency, and porphyria, excluding mild sensory neuropathy.
[0189] In an optional embodiment, the subject did not receive immunosuppressive therapy within one month prior to treatment with immunoglobulin G degrading enzymes. Alternatively, the subject did not receive azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, or prednisolone within one month prior to treatment.
[0190] In an optional embodiment, the subject is not a subject suffering from severe comorbidities. In an optional embodiment, the subject is not a subject suffering from malignant tumors, severe cardiovascular disease, severe chronic obstructive pulmonary disease (COPD), or severe infection.
[0191] In an optional embodiment, the dosage of immunoglobulin G degrading enzyme in each dose may be the same or different; in an optional embodiment, the dosage of immunoglobulin G degrading enzyme in the first dose is different from that in the supplementary dose, while the dosage of immunoglobulin G degrading enzyme in the supplementary dose is the same.
[0192] In an optional embodiment, the dosage of the first dose of immunoglobulin G degrading enzyme is about 0.1 mg / kg to about 1 mg / kg, and can be about 0.1 mg / kg to about 0.4 mg / kg, including but not limited to about 0.1 mg / kg, about 0.15 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.3 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 0.95 mg / kg, or about 1 mg / kg. The dosage of the supplemental immunoglobulin G degrading enzyme is approximately 0.1 mg / kg to approximately 0.3 mg / kg, optionally ranging from approximately 0.1 mg / kg to approximately 0.3 mg / kg, including but not limited to approximately 0.1 mg / kg, approximately 0.15 mg / kg, approximately 0.2 mg / kg, approximately 0.25 mg / kg, approximately 0.3 mg / kg, approximately 0.35 mg / kg, approximately 0.4 mg / kg, approximately 0.45 mg / kg, approximately 0.5 mg / kg, approximately 0.55 mg / kg, approximately 0.6 mg / kg, approximately 0.65 mg / kg, approximately 0.7 mg / kg, approximately 0.75 mg / kg, approximately 0.8 mg / kg, approximately 0.85 mg / kg, approximately 0.9 mg / kg, approximately 0.95 mg / kg, or approximately 1 mg / kg.
[0193] In an optional embodiment, the dosage of at least one dose of immunoglobulin G degrading enzyme is about 100% to about 20% of the dosage of the previous dose of immunoglobulin G degrading enzyme, optionally about 80% to about 40%, optionally about 50% to about 70%, optionally about 60%.
[0194] In an optional embodiment, the dosage of the first dose of immunoglobulin G degrading enzyme is 0.25 mg / kg; the dosage of the supplementary dose of immunoglobulin G degrading enzyme is 0.25 mg / kg or 0.15 mg / kg.
[0195] In an optional embodiment, the method can reduce the immunoglobulin G degradation enzyme level in the subject to about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% of the level before administration, 45 min to 6 h after administration.
[0196] In an optional embodiment, the method can reduce the immunoglobulin G degradation enzyme level in the subject to about 5 g / L, about 4 g / L, about 3 g / L, about 2 g / L, about 1 g / L or about 0.5 g / L or below 45 min to 6 h after administration.
[0197] In an optional embodiment, the administration interval of the immunoglobulin G degrading enzyme is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 9 days, 10 days, 13 days, or 14 days.
[0198] In an optional embodiment, the immunoglobulin G degrading enzyme is selected from IdeS, IdeE, IdeZ, IdeP, IdeSORK or their mutants.
[0199] In an optional embodiment, the immunoglobulin G degrading enzyme is a low-immunogenic immunoglobulin G degrading enzyme. Optionally, the immunogenic immunoglobulin G degrading enzyme has even lower immunogenicity than IdeS.
[0200] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme has at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with the amino acid sequence shown in any one of SEQ ID NO:1 to 13.
[0201] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme includes the amino acid sequence shown in any one of SEQ ID NO:1 to 13.
[0202] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme includes any one of the amino acid sequences shown in SEQ ID NO:1 to 11,16.
[0203] In an optional embodiment, the amino acid sequence of the immunoglobulin G degrading enzyme is shown in SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:13, or SEQ ID NO:16. Optionally, the immunoglobulin G degrading enzyme is the immunoglobulin G degrading enzyme with the amino acid sequence shown in SEQ ID NO:2.
[0204] In an optional implementation, the immunoglobulin G degrading enzymes in each dose may be the same or different.
[0205] In an optional implementation, the method includes:
[0206] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1; and
[0207] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2;
[0208] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0209] In an optional implementation, the method includes:
[0210] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1;
[0211] b. Administer supplemental dose of 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 on day 4; and
[0212] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2.
[0213] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0214] In an optional implementation, the method includes:
[0215] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1;
[0216] b. Administer supplemental dose of 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 on day 4; and
[0217] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2;
[0218] Optionally, subjects may receive concomitant treatment with prophylactic antibiotics or immunosuppressants.
[0219] In an optional implementation, the method includes:
[0220] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1;
[0221] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2;
[0222] c. On day 7, administer supplemental 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2; and
[0223] d. On day 10, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2.
[0224] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0225] In an optional implementation, the method includes:
[0226] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1; and
[0227] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16;
[0228] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0229] In an optional implementation, the method includes:
[0230] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1;
[0231] b. Administer supplemental dose of 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 on day 4; and
[0232] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16.
[0233] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0234] In an optional implementation, the method includes:
[0235] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1;
[0236] b. On day 4, administer supplemental dose of 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16; and
[0237] c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16;
[0238] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0239] In an optional implementation, the method includes:
[0240] a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16 intravenously on day 1;
[0241] b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16;
[0242] c. On day 7, administer supplemental dose of 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16; and
[0243] d. On day 10, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:16.
[0244] In an alternative implementation, the subject may receive concurrent treatment with prophylactic antibiotics or immunosuppressants.
[0245] A third aspect of this disclosure provides a pharmaceutical composition comprising an immunoglobulin G degrading enzyme sufficient for administration of the above-described method for treating diseases caused by pathogenic antiganglioside antibodies, and pharmaceutically acceptable excipients.
[0246] A fourth aspect of this disclosure provides a pharmaceutical combination comprising at least one immunoglobulin G degrading enzyme sufficient for administering the above-described method of treating a disease caused by pathogenic antiganglioside antibodies, and at least one of the above-described immunosuppressants and / or at least one of the above-described prophylactic antibiotics.
[0247] III. Examples
[0248] The present disclosure is further illustrated below with reference to embodiments. The description of specific exemplary embodiments of the present disclosure is for illustrative and explanatory purposes. These descriptions are not intended to limit the present disclosure to the precise forms disclosed, and it will be apparent that many changes and variations can be made in accordance with the teachings of this specification. The exemplary embodiments were chosen and described in order to explain the specific principles of the present disclosure and their practical application, thereby enabling those skilled in the art to implement and utilize various different exemplary embodiments of the present disclosure, as well as various different choices and variations.
[0249] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0250] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.
[0251] Example 1:
[0252] This study is a single-arm, open-label, dose-escalation phase II study designed to evaluate the preliminary efficacy, safety, and immunogenicity of IDEE-2 in patients with GBS.
[0253] Primary endpoint: The proportion of trial participants who improved by 1 point or more in their GBS Disability Scale (GBS-DS) at 4 weeks.
[0254] Secondary endpoint:
[0255] 1) Assess the average change in GBS-DS from baseline at each visit site during the study period;
[0256] 2) The proportion of trial participants who were able to walk independently (GBS-DS score of 2) at each visit point during the assessment study period;
[0257] 3) The time during which the participant's GBS-DS score improved by at least 1 point from baseline during the study period;
[0258] 4) The time during which participants were able to walk independently (GBS-DS score of 2) during the study period;
[0259] 5) Changes in the Medical Research Council muscle strength score (MRC) of trial participants during the study period.
[0260] In addition, it is necessary to monitor: 1) the incidence and severity of adverse events (AEs) and serious adverse events (SAEs);
[0261] 2) Pharmacokinetics;
[0262] 3) Pharmacokinetics. Assess changes in total IgG; assess changes in pathogenic IgG [including: antiganglioside antibodies (anti-GM1 or, GM2 or, GM3 or, GM4 or, GD1a or, GD1b or, GD2 or, GQ1b or, GT1a or, GT1b or anti-sulfatide antibodies, etc.]].
[0263] Main inclusion criteria:
[0264] 1. Age ≥ 18 years old, both male and female are acceptable;
[0265] 2. Diagnosed as classic GBS;
[0266] 3. The onset time of GBS was ≤10 days at the time of screening;
[0267] 4. Unable to walk independently within 10 meters (GBS-DS 3-4 points);
[0268] 5. Planned to receive IVIG or plasma exchange therapy;
[0269] 6. Subjects of childbearing age should not have any plans to have children during the study period and for 6 months after the end of the trial, or should use effective contraception during sexual intercourse;
[0270] 7. Fully understand the purpose and requirements of this experiment, be willing to comply with the requirements of the research protocol, and be able to sign a written informed consent form.
[0271] Main exclusion criteria:
[0272] 1. Previous treatment with IDEE-2;
[0273] 2. The screening period is during pregnancy or lactation;
[0274] 3. History of polyneuropathy with other causes [e.g., diabetes (excluding mild sensory neuropathy), alcoholism, peripheral polyneuropathy or porphyria associated with severe vitamin B1 deficiency];
[0275] 4. Known selective immunoglobulin A (IgA) deficiency;
[0276] 5. Received immunosuppressive therapy within the past month (e.g., azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, or prednisolone 20 mg daily, etc.);
[0277] 6. Individuals with known severe complications, such as malignant tumors, severe cardiovascular disease and severe chronic obstructive pulmonary disease (COPD), or severe infections.
[0278] 7. Known mental incapacity or language impairment that hinders full understanding of informed consent information and research activities;
[0279] 8. Has received other clinical trial drugs within 30 days prior to screening or within 5 half-lives (whichever is longer);
[0280] 9. The presence of any medical history or disease that the investigator believes may pose an unacceptable risk to the participant's participation in the study;
[0281] 10. History of known allergy to any component of IDEE-2 or any related product (including excipients in the formulation), or severe allergic reaction to any medication (e.g., angioedema).
[0282] 11. Laboratory indicators meet one or more of the following:
[0283] Alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN);
[0284] Aspartate aminotransferase (AST) > 3 × ULN.
[0285] 12. The virological test results during the screening period meet one or more of the following criteria: 1) Hepatitis B surface antigen (HBsAg) positive or hepatitis B core antibody (HBcAb) positive; 2) Hepatitis C virus antibody (HCV-Ab) positive; 3) Human immunodeficiency virus antibody (HIV-Ab) positive; 4) Treponema pallidum antibody (TP-Ab) positive.
[0286] Dosing regimen
[0287] The enrolled subjects received treatment via dosing regimen 1 and dosing regimen 2 in the order of enrollment.
[0288] The control group received either plasma exchange or intravenous immunoglobulin (IVIG). The following treatment regimens are recommended, but the specific regimen will be determined by the investigator:
[0289] 1) IVIG treatment regimen: 400 mg / kg / day, once a day, intravenous infusion, for 5 consecutive days (D1-D5).
[0290] 2) Plasma exchange therapy regimen: The amount of plasma exchanged each time is 30-50 ml per kilogram of body weight, and it is performed 4-5 times within 1-2 weeks.
[0291] The safety, efficacy, and immunogenicity data generated during the observation period were evaluated.
[0292] Blood samples were collected from the experimental group within 60 minutes before the first dose, 6 hours (±15 minutes) after the first dose, 24 hours (±30 minutes) after the first dose, 48 hours (±30 minutes) after the first dose, within 60 minutes before each supplementary dose, 6 hours (±15 minutes) after each supplementary dose, D10 (±1 day), D14 (±1 day), D21 (±2 days), D28 (±3 days), and D56 (±7 days) to detect total IgG, [scIgG, F(ab')2, Fc], and pathogenic IgG.
[0293] Immunogenicity assessment: Assess changes in anti-drug antibody (ADA) levels at different time points.
[0294] Table 1. Dosing regimen for the experimental group
[0295] Based on the specific circumstances of each patient, the researchers may determine whether the subjects can receive concurrent treatments such as prophylactic antibiotics and immunosuppressants, as well as respiratory function management, swallowing function management, nutritional support, neurotrophic repair therapy, rehabilitation therapy, and treatment for complications.
[0296] GBS Disability Scale (GBS-DS):
[0297] Medical Research Council Muscle Strength Rating (MRC):
[0298] The sum of MRC scores for six bilateral muscle groups, including arm abduction, forearm flexion, wrist extension, leg flexion, knee extension, and foot dorsiflexion, ranges from 60 (normal) to 0 (quadriplegia). The MRC score for a single muscle group ranges from 0 to 5.
[0299] 0: No visible shrinkage
[0300] 1: Visible contraction, no limb movement (not present when hip joint is flexed)
[0301] 2: The limbs can move, but cannot resist gravity.
[0302] 3: Able to defy gravity and perform (almost) the full range of motion.
[0303] 4: Capable of resisting gravity and resistance movement
[0304] 5: Normal
[0305] Some data are shown in Figure 9. Data from scheme 1 show that GBS-DS began to improve on the first day after medication; by the fourth day, GBS-DS had dropped to 2 and remained stable thereafter until the ninth day; muscle strength improved shortly after medication and was close to normal by the ninth day, indicating that muscle strength was significantly restored.
[0306] Figure 9 shows that both GBS-DS and MRC scores improved to varying degrees after drug administration, demonstrating that muscle strength was significantly restored after treatment with IDEE-2.
[0307] Example 2:
[0308] Clinical studies evaluating IdeE-2 injection for the treatment of acute severe autoimmune diseases mediated by pathogenic immunoglobulin G (IgG) autoantibodies (e.g., anti-glomerular basement membrane antibody-associated diseases, anti-GBM disease) were conducted, with acute remission in each study cohort as the primary efficacy endpoint.
[0309] Treatment regimen: On day 1, administer IDEE-2 intravenously at a dose of 0.25 mg / kg. To prevent rebound of anti-GBM antibody levels, administer an additional 0.15 mg / kg of IDEE-2 on day 8 (the investigator may decide to administer one or more doses of 0.15 mg / kg of IDEE-2 on days 3–10, depending on the level of anti-GBM antibody). Patients will receive immunosuppressants (such as glucocorticoids, cyclophosphamide, etc.) as prescribed according to the clinical practice of each research center.
[0310] Option 1: Administer IDEE-2 intravenously at a dose of 0.25 mg / kg on day 1 (D1), and then administer IDEE-2 again at a dose of 0.15 mg / kg on day 8 (D8, which can be advanced or delayed from D3 to D10 depending on the level of anti-GBM antibody), for a total of two treatments.
[0311] Option 2: Administer IDEE-2 intravenously at a dose of 0.25 mg / kg on day 1 (D1), followed by an infusion of IDEE-2 at a dose of 0.15 mg / kg on day 4 (D4) and day 7 (D7), for a total of three treatments.
[0312] Option 3: IDEE-2 was administered intravenously at a dose of 0.25 mg / kg on day 1 (D1), followed by four infusions of 0.15 mg / kg IDEE-2 on days 4 (D4), 7 (D7), and 10 (D10). Patients were enrolled sequentially for these three dosing regimens. During the study, patients received combination therapy with glucocorticoids and cyclophosphamide.
[0313] Inclusion criteria:
[0314] 1. Age ≥ 18 years old, both male and female are acceptable;
[0315] 2. Clinically diagnosed with anti-GBM disease. Screening showed positive anti-GBM antibodies, with / without concurrent ANCA antibody positivity.
[0316] Ten subjects who met the inclusion criteria were numbered S01 to S10. Subjects S01 to S06 received a two-dose regimen on D1 and D8, while subjects S07 to S10 received a three-dose regimen on D1, D4, and D7. No infection or other infusion-related reactions were reported by any of the subjects, indicating that IdeE-2 has good tolerability and safety.
[0317] The detection method for ADA is as follows: This experiment uses an ELISA bridging method to determine anti-IDEE-2 antibodies in human serum. In the screening experiment, a certain amount of IDEE-2 antigen is coated on the ELISA plate to capture anti-IDEE-2 antibodies in the serum. The captured antibodies then bind to biotinylated IDEE-2, and subsequently react with Streptavidin-Peroxidase from Streptomyces avidinii. The signal value is positively correlated with the antibody concentration in the sample. Samples with high signal values are considered to have potential anti-IDEE-2 antibodies in their serum. In the confirmatory experiment, externally added IDEE-2 is used to inhibit the anti-IDE-2 antibodies in the serum, i.e., a confirmatory test is performed on samples that are potentially antibody-positive. The higher the signal inhibition rate, the higher the titer of anti-IDEE-2 antibodies in human serum.
[0318] Figures 1–4 illustrate the crucial role of repeated IDEE-2 dosing in diseases requiring a prolonged therapeutic window. In the treatment of autoantibody-mediated conditions, repeated IDEE-2 dosing can reduce pre-existing IgG levels to an acceptable range. Furthermore, repeated IDEE-2 dosing provides a longer low IgG window, allowing for more thorough pretreatment assessment before administration of autoimmune therapies. Moreover, this approach could offer a potential solution for overcoming the neutralizing antibody barrier, enabling multi-round autoimmune therapy.
[0319] Figures 5-8 show that after three repeated doses of IDEE-2, serum IgG levels significantly decreased to near zero 6 hours after the first dose and remained at very low levels for the following 10 days, before gradually and slowly recovering. Serum anti-GBM antibodies in all patients also rapidly decreased to near zero 6 hours after the first dose and remained at this level throughout the follow-up period, demonstrating significant efficacy. Furthermore, ADA production began on day 10. The three-dose regimen can play a crucial role in diseases requiring a prolonged therapeutic window, providing a more stable and reliable treatment window.
[0320] The above results demonstrate that IDEE-2 has a rapid onset of action and can effectively clear pathogenic IgG antibodies in a short period of time, thereby significantly reducing further damage to organs and tissues caused by autoimmune responses. The results of the two- and three-dose trials provide clinical evidence for using multiple doses of IDEE-2 to reduce IgG levels, overcoming the antibody-mediated challenges of multiple dosing in the treatment of autoantibody-mediated diseases, and providing a potential strategy for ultimately improving treatment outcomes for these diseases. Furthermore, this method may offer a potential solution for overcoming the neutralizing antibody barrier, enabling multi-round dosing therapy for autoantibody-mediated diseases and improving overall treatment efficacy.
[0321] Example 3
[0322] IgG degrading enzyme activity was detected by enzymatic digestion of purified protein followed by capillary electrophoresis. Trastuzumab substrate was diluted to 10 mg / ml with water for injection, and the enzyme sample was diluted to 0.01 mg / ml. The pH was adjusted to 7.0 ± 0.1 using 5× phosphate buffer. A 200 μl reaction mixture of enzyme and substrate was prepared at a 1:5000 mass ratio using 5× phosphate buffer and incubated at 37 ± 1 °C for 60 ± 10 min. The digestion reaction was terminated by water bath at 70 °C for 10 min to obtain the pre-treated sample.
[0323] Take 20 μl of the pre-treated sample, add 75 μl of SDS-MW Sample Buffer and 5 μl of 0.25 mol / L iodoacetamide aqueous solution, and vortex to mix. Incubate at 65 °C for 4 minutes, cool to room temperature, vortex to mix again, and centrifuge at 4500 g for 1 minute. Take 90 μl of the sample to be tested for non-reducing CE-SDS separation, record the chromatogram at 220 nm wavelength, and record data for 40 minutes. Calculate the proportions of Fc, F(ab')2, scIgG, and IgG within the integration window using the area normalization method.
[0324] Table 2 Results of IgG Degrading Enzyme Activity Detection
[0325] The test results showed that the activities of IdeS, HIGES2, and IM3 were comparable, the remaining amount of scIgG was not significantly different, IM1 and IM2 could completely cleave the substrate, and ISK enzyme activity was the lowest.
[0326] Example 4
[0327] To evaluate the effect of IgG degrading enzymes on ADA in the presence of immunosuppressants. Male New Zealand rabbits were selected and administered the enzyme test product intravenously, while the immunosuppressant, cyclophosphamide, a commonly used clinical drug, was administered via gavage. Groups 1-4 received the enzyme test product once on days 1 and 8, while groups 3-4 received cyclophosphamide once daily from day 3 to day 15. Blood samples were collected before administration on day 1, 1 hour after administration on day 1, before administration on day 8, 1 hour after administration on day 8, and on day 15. The levels of ADA corresponding to IDEE-2 and HIGES2 in the blood were measured using ELISA.
[0328] Anti-drug antibodies in serum were measured using an ELISA bridging method. A certain amount of drug was coated on an enzyme-labeled plate to capture anti-drug antibodies in serum. The captured antibodies then combined with biotinylated drug, and subsequently reacted with Streptavidin-Peroxidase from Streptomyces avidinii. The SNR value was positively correlated with the antibody concentration in the sample.
[0329] Figure 9 shows that both groups 1 and 2, without immunosuppressants, produced relatively higher levels of ADA by day 15 compared to pre-administration levels, while the immunosuppressant groups showed suppressed ADA production. Even the more immunogenic enzyme HIGES2 could suppress high ADA production under immunosuppressant action.
[0330] Table 3 Experimental groups showing the effect of IgG degrading enzymes on ADA in the presence of immunosuppressants.
[0331] sequence list
[0332] The foregoing is a further detailed description of this disclosure and should not be construed as limiting its specific implementation. All documents mentioned in this disclosure are incorporated herein by reference as if each document were individually incorporated by reference. Furthermore, it should be understood that simple deductions or substitutions made by those skilled in the art to which this disclosure pertains, without departing from the concept of this disclosure, are within the scope of protection of this disclosure.
Claims
1. A method for treating a disease caused by pathogenic antiganglioside antibodies, the method comprising: a. Administer a first dose of immunoglobulin G degrading enzyme to the subject intravenously on day 1 at a dose of approximately 0.1 mg / kg to approximately 1 mg / kg; and b. Administer immunoglobulin G degrading enzymes to the subject at intervals of 1 to 14 days, at a dose of approximately 0.1 mg / kg to approximately 1 mg / kg.
2. The method of claim 1, wherein, The method comprises administering the subject approximately 0.1 mg / kg to approximately 1 mg / kg of immunoglobulin G degrading enzyme within 24 hours after the first administration of the enzyme.
3. The method of claim 1 or 2, wherein, The method includes repeating step b at least once; Optionally, the method includes repeating step b two or three times.
4. The method of any one of claims 1-3, wherein, The subjects also received treatment with at least one immunosuppressant or prophylactic antibiotic.
5. The method of any one of claims 1-4, wherein, When the condition progressively worsens 12 hours after the last administration of immunoglobulin G degrading enzyme, IVIG and PE salvage therapy can be initiated. Optionally, the progressive worsening of the condition includes severe respiratory distress.
6. The method of any one of claims 1 to 5, wherein, The antiganglioside antibody includes at least one of the following: anti-GM1 antibody, anti-GM2 antibody, anti-GM3 antibody, anti-GM4 antibody, anti-GD1a antibody, anti-GD1b antibody, anti-GD2 antibody, anti-GQ1b antibody, anti-GT1a antibody, anti-GT1b antibody, or anti-sulfatide antibody.
7. The method of any one of claims 1 to 6, wherein, The diseases mentioned include Guillain-Barré syndrome (GBS), Miller-Fischer syndrome (MFS), multifocal motor neuropathy (MMN), or chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
8. The method of any one of claims 1-7, wherein, The subjects were patients with acute GBS. Optionally, the subject's onset time is ≤10 days.
9. The method of any one of claims 1-8, wherein, The subjects were not subjects with selective immunoglobulin A (IgA) deficiency.
10. The method of any one of claims 1-9, wherein, The subjects had no history of polyneuropathy due to other causes; Optionally, the history of polyneuropathy for other causes is selected from the group consisting of diabetes, alcoholism, peripheral polyneuropathy associated with severe vitamin B1 deficiency, and porphyria, excluding mild sensory neuropathy.
11. The method of any one of claims 1-10, wherein, The subjects did not receive immunosuppressive therapy within one month prior to receiving immunoglobulin G degrading enzyme treatment; Optionally, the subject had not received azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, or prednisolone within one month prior to treatment.
12. The method of any one of claims 1-11, wherein, The subjects were not those suffering from severe comorbidities; Optionally, the subject is not a subject suffering from malignant tumors, severe cardiovascular disease, severe chronic obstructive pulmonary disease (COPD), or severe infection.
13. The method of any one of claims 1-12, wherein, The dosage of immunoglobulin G degrading enzyme may be the same or different for each dose; Optionally, the dosage of immunoglobulin G degrading enzyme in the first dose is different from that in the supplemental dose, while the dosage of immunoglobulin G degrading enzyme in the supplemental dose is the same.
14. The method of any one of claims 1-13, wherein, The dosage of the first dose of immunoglobulin G degrading enzyme is approximately 0.1 mg / kg to approximately 1 mg / kg, with an option of approximately 0.1 mg / kg to approximately 0.4 mg / kg; the dosage of the supplemental dose of immunoglobulin G degrading enzyme is approximately 0.1 mg / kg to approximately 1 mg / kg, with an option of approximately 0.1 mg / kg to approximately 0.3 mg / kg.
15. The method of any one of claims 1-14, wherein, The dosage of at least one dose of immunoglobulin G degrading enzyme is approximately 100% to approximately 20% of the previous dose of immunoglobulin G degrading enzyme, optionally approximately 80% to approximately 40%, optionally approximately 50% to approximately 70%, optionally approximately 60%.
16. The method of any one of claims 1-15, wherein, The dosage of the first dose of immunoglobulin G degrading enzyme is 0.25 mg / kg; the dosage of the supplementary dose of immunoglobulin G degrading enzyme is 0.25 mg / kg or 0.15 mg / kg.
17. The method of any one of claims 1-16, wherein, The method, after administering the first dose of immunoglobulin G degrading enzyme for 45 minutes to 6 hours, can reduce the immunoglobulin G level in the subject to approximately 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.5% of the pre-administration level.
18. The method of any one of claims 1-17, wherein, The method described above can reduce the level of immunoglobulin G in the subject to about 5 g / L, about 4 g / L, about 3 g / L, about 2 g / L, about 1 g / L or about 0.5 g / L or below 45 min to 6 h after administration of the first dose of immunoglobulin G degrading enzyme.
19. The method of any one of claims 1-18, wherein, The administration intervals for the immunoglobulin G degrading enzyme are 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 9 days, 10 days, 13 days, or 14 days.
20. The method of any one of claims 1-19, wherein, The immunoglobulin G degrading enzyme is selected from IdeS, IdeE, IdeZ, IdeP, IdeSORK or their mutants.
21. The method of any one of claims 1-20, wherein, The immunoglobulin G degrading enzyme is a low-immunogenic immunoglobulin G degrading enzyme. Optionally, the immunogenic immunoglobulin G degrading enzyme has lower immunogenicity than IdeS.
22. The method of any one of claims 1-21, wherein, The amino acid sequence of the immunoglobulin G degrading enzyme has at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with the amino acid sequence shown in any of SEQ ID NO:1 to 13, 16.
23. The method of any one of claims 1-22, wherein, The amino acid sequence of the immunoglobulin G degrading enzyme includes any one of the amino acid sequences shown in SEQ ID NO: 1 to 13, 16.
24. The method of any one of claims 1-23, wherein, The amino acid sequence of the immunoglobulin G degrading enzyme includes any one of the amino acid sequences shown in SEQ ID NO: 1 to 11, 16.
25. The method of any one of claims 1-24, wherein, The amino acid sequence of the immunoglobulin G degrading enzyme is shown in SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:13 or SEQ ID NO:16; Optionally, the immunoglobulin G degrading enzyme is the immunoglobulin G degrading enzyme with the amino acid sequence SEQ ID NO:
2.
26. The method of any one of claims 1-25, wherein, The immunoglobulin G degrading enzymes in each dose may be the same or different.
27. The method of any one of claims 1-26, wherein, The method includes: a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1; and b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2; Optionally, subjects may receive concomitant treatment with prophylactic antibiotics or immunosuppressants.
28. The method of any one of claims 1-26, wherein, The method includes: a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1; b. Administer supplemental dose of 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 on day 4; and c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2; Optionally, subjects may receive concomitant treatment with prophylactic antibiotics or immunosuppressants.
29. The method of any one of claims 1-26, wherein, The method includes: a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1; b. Administer supplemental dose of 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 on day 4; and c. On day 7, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2; Optionally, subjects may receive concomitant treatment with prophylactic antibiotics or immunosuppressants.
30. The method according to any one of claims 1 to 26, wherein, a. Administer 0.25 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2 intravenously on day 1; b. On day 4, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2; c. On day 7, administer supplemental 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2; and d. On day 10, administer 0.15 mg / kg of the immunoglobulin G degrading enzyme shown in SEQ ID NO:2; Optionally, subjects may receive concomitant treatment with prophylactic antibiotics or immunosuppressants.
31. A pharmaceutical composition, wherein, The pharmaceutical composition comprises an immunoglobulin G degrading enzyme sufficient to administer the method of treating a disease caused by pathogenic antiganglioside antibodies as described in any one of claims 1 to 30, and pharmaceutically acceptable excipients.
32. A pharmaceutical combination wherein, The drug combination comprises at least one immunoglobulin G degrading enzyme sufficient to administer the method of treating a disease caused by pathogenic antiganglioside antibodies as described in any one of claims 1 to 30, and at least one immunosuppressant and / or at least one prophylactic antibiotic.
